Drugs are widely recognized to vary in the beneficial and undesirable effects they produce in human subjects. The understanding that variants (polymorphisms and mutations) in the human genome are common and may well modulate both disease and its response to drugs, is a critical new concept in understanding mechanisms of drug action and their variability in human subjects. Variability can arise because of variability in genes encoding molecules of drug disposition, in genes encoding molecules that drugs target, or in genes that modulate the overall activity of the complex biological systems within which drugs act. The evolving understanding of the genetic basis of variability in response to drugs used in the treatment of sudden cardiac death has important implications not only for the treatment of patients who have survived an episode, but also for helping formulate a framework for further understanding mechanisms of drug action at the genetic level.
Introduction
genetically determined arose in the early part of the 20th Century when the British physician Garrod first proposed It is near-axiomatic that individuals vary in their rethat the enzymatic pathways defective in unusual metabolsponse to any drug therapy. The sources of such variability ic diseases (such as porphyria) might also confer unusual have been traditionally classified as 'pharmacokinetic' and sensitivity to certain exogenous agents [1] . These early 'pharmacodynamic'. Pharmacokinetic variability refers to thoughts were reinforced by the recognition during the variability in the conventional measures of a drug disposiSecond World War of development of hemolytic anemia tion: absorption, distribution, metabolism, and elimination. during exposure to anti-malarial drugs among individuals Inter-individual variability in these processes are well-(usually African-Americans) with G6PD deficiency. These recognized as sources of variability in the delivery of drug pharmacodynamic examples were followed by definition of to, and removal of drug from important extracellular and familial defects in drug metabolism as a source of variintracellular sites of action. It is by interacting with target ability in drug action or unusual drug effects. In the 1950s, molecules at these sites that drugs actually exert their familial pseudocholinesterase deficiency, leading to probeneficial and detrimental effects. Even in the absence of longed paralysis after exposure to succinylcholine, was any pharmacokinetic source of variability in drug action, identified [2] . The first identified common inherited trait patients may vary substantially in response. This is termed determining drug action was that responsible for eliminapharmacodynamic variability, and underlying mechanisms tion by N-acetylation of drugs such as procainamide and -which may be complex -are discussed further below.
isoniazid [3] . Slow acetylators develop a higher incidence of the lupus syndrome during procainamide therapy [4] , and rapid acetylators have a higher risk for neuropathy 2. Pharmacogenetics and pharmacogenomics during isoniazid therapy. The 1970s saw identification of the 'poor metabolizer' (PM) trait for substrates of the The notion that unusual responses to drugs might be cytochrome P4502D6 (now termed CYP2D6) [5, 6] . Although CYP2D6 is not abundantly expressed in liver (by weight), it metabolizes many drugs in common use, selected population. Most polymorphisms occur at inincluding some (but by no means all) antiarrhythmics, dividual nucleotides ('single nucleotide polymorphisms', antidepressants, and beta-blockers. Description of familial often referred to as 'SNPs'). Other polymorphisms occur CYP2D6 deficiency was followed by identification of as repeats of dinucleotides or other groupings, or as large individuals with defective metabolism of warfarin and of insertions or deletions. Some of these polymorphisms the anti-seizure drug mephenytoin; these familial defects occur in coding regions of genes, and therefore may or were not co-inherited, i.e. they reside at separate genetic may not change the encoded amino acid. Others occur in loci, and since have been shown to result from DNA non-coding regions but nevertheless may modulate regulavariants in the genes encoding CYP2C9 and CYP2C19, tion of expression of individual genes. It is estimated that respectively. Importantly, these unusual responses to drug 'the' human genome includes |3,000,000 SNPs. therapy were defined by astute clinical observation and family study; no specific gene defect was identified, since genes were not yet accessible for study. Thus, the field of 3. The clinical pharmacology of antiarrhythmic drugs pharmacogenetics had its start even before DNA was identified as the carrier of genetic information in human Drug therapy of cardiac arrhythmias has been parbeings. Indeed, more contemporary genetic studies have ticularly instructive for pharmacokinetics, pharmacodyrevealed that 'the' PM phenotype can arise as a result of namics, and pharmacogenetics because the margin between dozens of mutations in the CYP2D6 gene [7] . Moreover, drug doses and concentrations producing efficacy and occasional subjects with CYP2D6 gene duplication and a those associated with toxicity (including sudden cardiac resultant 'ultra-rapid' metabolizer phenotype have been death) may be quite small. Thus, the lessons learned in the described [8] .
study of interindividual variability in response to antiarMost drugs currently used to treat arrhythmias and other rhythmic drugs have had widespread applicability to other human diseases were developed at a time when the areas of drug therapy. The last five years have seen molecular basis of drug action was not well-understood.
enormous advances in our understanding of rare geneticThus, many available agents are 'dirty', in the sense that ally defined arrhythmia syndromes, such as the long QT they target multiple molecules to produce their desirable syndrome and the Brugada syndrome. Such advances have and undesirable effects. As our understanding of the not only helped understand pathogenesis in these molecular basis of drug disposition and of drug interacsyndromes, but have also provided a starting point for tions with their targets becomes more sophisticated, it is studies of the way in which variability in function or not only possible to refine our understanding of the expression of these (and many other) genes can modulate mechanism of action of older drugs, but also to develop response to drugs. Thus, the lines of distinction between newer ones that should be 'cleaner'. However, it is well-defined genetic syndromes (discussed in other reviews becoming clearer that the clinical actions of even 'clean' in this issue of Cardiovascular Research) and phardrugs (that interact with only a single target molecule) macogenetics are blurred. Moreover, this is but one depend on the normal function of multiple molecules, manifestation of the general rule that identification of the including those involved in drug disposition as well as genetic basis of disease carries with it important implicathose modulating the drug-target interactions and the larger tions for understanding variability in drug treatment of that biologic context in which that interaction occurs. This disease. appreciation of the multi-molecular basis of clinical drug actions in turn has led naturally to identification of the specific genes and pathways that form the basis for these 4. Interpreting variability in drug action in a molecular events. The identification of variants in multiple molecular context: an example genes modulating drug action in turn defines a newer approach to understanding variability in drug action, Fig. 1 expands these theoretical considerations into a pharmacogenomics. The ultimate concept, which remains practical context for the following discussion. One drug to be validated, is that drug response may be predictable by target that has assumed some importance in the broad area defining not single variants (as in the pharmacogenetic of the pharmacogenetics of sudden death is the rapidly examples) but by defining relatively large sets of variants activating component of delayed rectifier current in heart, that, together, create a pathophysiologic milieu more or I [13] . This current is generated by expression of the Kr less likely to result in a desirable drug effect [9] [10] [11] . Human Ether-a-go-go Related Gene (HERG), and moduTwo general types of genetic variants are described: lated by at least one ancillary subunit, MiRP1 [14, 15] . mutations and polymorphisms [12] . Mutations are generalMutations in HERG or MiRP1 cause the congenital long ly defined as disease-associated alterations in DNA, occur-QT syndrome, and most drugs causing torsades de pointes ring in rare (generally less than 1%) patients. Polymorare I blockers. Variability in pharmacokinetics (i.e. in lite(s)) to the intracellular vestibule of the HERG channel, these other repolarizing currents have been described in its site of action. However, variability in response may also cases of I -related torsades de pointes [16] [17] [18] [19] . With the identification of molecular defects in I as the thromycin) and azole anti-fungal drugs (ketoconazole, Ks commonest cause of the congenital long QT syndrome, itraconazole) [27] . these drug development efforts were terminated.
Genetic defects resulting in absence of CYP3A4 activity might be expected to produce terfenadine-associated tor-5.1. Pharmacokinetics of drug-associated torsades de sades de pointes at usual doses, in the absence of inhibitor pointes -concentration-dependence drugs (or overdose). However, such cases are extremely unusual, in keeping with the fact that no cases of genetic When the data are available, the risk of torsades de defects resulting in absence of CYP3A4 activity have yet pointes increases as a function of drug dose or conbeen reported. The situation for the gastric prokinetic drug centration. This is true for antiarrhythmic agents (sotalol cisapride is near-identical: inhibition of the drug's extenand dofetilide) as well as cisapride, terfenadine, and sive pre-systemic clearance by CYP3A4 is the cause of astemizole, destined for non-cardiovascular indications.
most cases of cisapride-associated torsades de pointes [28] . The one major exception appears to be quinidine, where
It should be emphasized that these spectacular clinical the risk is well-recognized even after single dose and at examples arise because the parent drugs are potent I Kr low concentrations. In vitro studies have identified quiniblockers and because there is only a single pathway dine as a potent I blocker [26] , but the drug also blocks determining their disposition. The situation with respect to Kr inward currents through sodium and calcium channels at astemizole is somewhat more complicated, as the drug high concentrations. Indeed, in vitro studies indicate that, undergoes metabolism by at least two pathways, and one as concentration of quinidine is increased, action potential of the active metabolites is also an I blocker [29] .
Kr first prolongs (reflecting I block) and then in fact The possibility exists, and indeed is likely, that inhibiKr shortens, presumably reflecting block of inward currents. tion of other pathways might increase the risk of torsades This multiplicity of quinidine actions likely accounts for de pointes for other substrates. This is probably bestthe lack of concentration-dependence that quinidine-indeveloped for the anti-schizophrenic drug thioridazine duced torsades de pointes. Further, it carries the very (Mellaril). Thioridazine is a CYP2D6 substrate [30] and is important message that variability in other elecalso an I blocker [31] . Some data suggest that the risk of Kr trophysiologic actions (notably calcium and sodium current thioridazine-associated torsades de pointes is increased by block), and by extension the genes underlying those co-administration of CYP2D6 (but not CYP3A4) inactions, can strongly modulate the likelihood and conhibitors, and the drug's labeling was changed in midcentration dependence of I -induced torsades de pointes.
2000 to restrict its use, given this newer understanding
Kr
Given that the risk of torsades de pointes increases with of its potential risks (http: / / www.fda.gov / cder / ogd / rld / increasing drug concentration, it follows naturally that 17923s48.PDF). The most potent CYP2D6 inhibitor idendrug interactions that increase plasma concentrations of I tified is quinidine, which can inhibit the enzyme at dosages Kr blockers should increase risk of torsades de pointes. The far lower than those used clinically (e.g. ,50 mg). extent to which the block of a single pathway of drug However, in practice, very few patients receive quinidine disposition alters risk for torsades de pointes depends on and thioridazine. Some antidepressants (from both tricyclic the importance of that pathway in the overall disposition of and selective serotonin re-uptake inhibitor classes) are also a specific drug. Quinidine is metabolized by multiple CYP2D6 inhibitors and are much more likely to be used in pathways and also undergoes renal excretion. Thus, inhibipatients receiving thioridazine. Similarly, many tricyclic tion of a single pathway of quinidine disposition is not a antidepressant drugs are themselves CYP2D6 substrates. well-recognized risk factor for quinidine-associated torTricyclic antidepressant overdose is well-recognized as a sades de pointes. On the other hand, the antihistamine cause of arrhythmias, although typically the arrhythmia is terfenadine undergoes rapid and near-complete pre-sysnot torsades de pointes but a monomorphic tachycardia temic metabolism by the cytochrome P4503A4 (CYP3A4), likely related to excess sodium channel block. At usual which is expressed in both liver and intestinal epithelium.
dosages, it is not clear that inhibition of a single pathway This extensive pre-systemic metabolism results in very low of metabolism strongly affects the likelihood of torsades de pointes by tricyclics, particularly as many have multiple morphisms, each occurring in 1-2% of the general populapathways of drug disposition. Comprehensive information tion (one in MinK, one in MiRP1), that appear to increase on substrates, inhibitors, and inducers of cytochrome the likelihood of drug-induced torsades de pointes P450s is presented at http: / / www.georgetown.edu / depart- [15, 16, 19] . ments / pharmacology / davetab.html.
Pharmacodynamics of drug-associated torsades de
6. Molecular markers of drug toxicity -QT interval pointes -extracellular potassium prolongation and the drug development process
Hypokalemia has long been recognized to prolong the The examples of terfenadine and cisapride (and other QT interval (even in the absence of drug) and to increase drugs such as terodiline, halofantrine, lidoflazine, bepridil, the risk of drug-induced torsades de pointes [32, 33] . and ketanserin) that caused torsades de pointes during the patients, identifies subjects with torsades de pointes, then ing action of extracellular sodium [36] . Importantly, we the risk is judged relatively large, and the drug is unlikely have shown that drug block of I is strongly dependent on Kr to be marketed. However, if the risk of torsades de pointes is small (e.g. ,1 / 10,000), then a typical drug development concentration of quinidine or dofetilide to block 50% of I Kr program may not identify any cases whatsoever. In this by 10-40 fold [26] . This finding likely contributes to the case, further development and marketing presents a parmarkedly enhanced risk of drug-induced torsades de ticular problem for the drug industry and for drug regpointes with hypokalemia.
ulators. On the one hand, the risk of torsades de pointes may be very small, or even non-existent, depending on the 5.3. Other risk factors size of the preclinical 'signal' in terms of QT prolongation and / or I block. On the other hand, there may be a
Kr
Other risk factors for torsades de pointes have been substantial risk that is simply not uncovered by a reasonidentified, but the molecular basis whereby they increase able pre-marketing program. risk are not well-understood. These include female gender
Regulators have become aware of this problem, and are [37] , rapid drug administration by the intravenous route now regularly requesting relatively detailed QT interval [38] , recent conversion from atrial fibrillation [39] , the and other evaluations (e.g. multiple ECGs) during drug presence of congestive heart failure or cardiac hypertrophy, development (http: / / www.eudra.org / humandocs / PDFs / hypomagnesemia, and prolonged baseline QT interval SWP/ 098696en.pdf). In industry, there appears to be great (including patients with unrecognized congenital long QT sensitivity to I block as a marker for potential adverse Kr syndrome) [40, 41] . It seems reasonable to postulate that drug effects. In practice, these issues are being worked out these risk factors act to reduce net repolarizing current on a case by case basis, and require consideration of not (whether through I or other currents) thereby reducing only the risks of torsades de pointes conferred by an Kr what we have previously termed 'repolarization reserve'. individual drug, but also potential benefits, particularly The concept is that multiple ion currents contribute to with respect to alternate forms of therapy that may be normal repolarization, and it is likely that in many patients available; these issues are discussed in further detail in a reduction in one of these redundant mechanisms will not recent Policy Conference summary [42] . These debates cause torsades de pointes. Most patients have multiple risk have most recently occurred over new antibiotics and new factors, implying that each one contributes to reduction of antipsychotic drugs. Importantly, the use of HERG block repolarizing current, and then superimposition of challenge as a potential (and as yet unvalidated) model for drug by an I blocker results in failure of repolarization and toxicity is a non-specific example of the more general Kr torsades de pointes. It is in this context that one can thus problem of using an increasing understanding of the best understand how patients may carry 'subclinical' long molecular basis of drug action to predict drug toxicity. It QT syndrome that only becomes manifest on drug exposeems likely that the regulatory and industrial response to sure. The extent to which this phenomenon underlies risk the QT /I issue will lay the groundwork for subsequent Kr for drug-associated torsades de pointes is not yet known. In responses to new molecular or genetic markers for other addition to sporadic cases of mutation presenting in this forms of drug toxicity (e.g. hepatotoxicity or bone marrow fashion [17, 18] , we and others have identified two polysuppression), as these are identified.
7. Other drug-induced sudden cardiac death drug-induced arrhythmias and sudden death are relatively well-recognized and their mechanisms increasingly wellDefects in the cardiac sodium channel have been understood. By contrast, the mechanisms whereby drugs identified in some patients with structurally normal hearts act to prevent sudden death, and indeed the mechanisms and 'idiopathic' ventricular fibrillation (IVF) or the whereby sudden death occurs, are much less well underelectrocardiographically distinctive variant, the Brugada stood and more heterogeneous. Thus, a genetic framework syndrome. The parallels between this entity and the long for understanding variability in the therapeutic response to QT syndrome with respect to drug challenge are interestdrug therapy targeted at prevention of sudden death is ing. Just as patients with subclinical mutations in long QT much less accessible to available approaches. With the disease genes may present with normal ECGs, patients development of large databases with well-characterized with the Brugada syndrome may have normal ECGs. In drug responses and DNA samples (with appropriate conboth cases, drug challenge (with a QT prolonging drug in trols), may come the possibility of applying pharthe long QT syndrome or a sodium channel blocking drug macogenomic approaches to identification of sets of polyin the IVF / Brugada syndrome) may expose the electromorphisms likely to predict desired drug effect. At this cardiographic phenotype [43, 44] . In the long QT point, it is not possible to identify specific genetic markers syndrome, the sense is that such exposure increases the that will predict a beneficial effect during drug therapy to risk for torsades de pointes. Much less data are available prevent sudden death. with respect to the Brugada syndrome, but exposure of the Drugs demonstrated to prevent sudden cardiac death in ECG phenotype by drug challenge may well increase the clinical trials include beta-blockers and ACE inhibitors. risk of ventricular fibrillation [45] . These considerations Polymorphisms in specific disposition pathways and in further emphasize the extent to which identification of the target molecules have been identified for members of both genetic basis of disease is intimately linked to the genetic classes. Many, but certainly not all, beta blockers are basis for variability in response to drug therapy.
CYP2D6 substrates: metoprolol, timolol, and carvedilol are In vitro studies suggest that the mechanism underlying prominent examples. The formal possibility, therefore, ventricular fibrillation in the Brugada syndrome is exaggerexists that ultra-rapid CYP2D6 metabolizers could be ated shortening of action potential duration in epicardium exposed to less beta blockade and protection might be versus endocardium, as a consequence of sodium channel greatest among patients with the PM trait. These concepts block [46, 47] . Interestingly, simulated myocardial ishave not been validated. Common polymorphisms in the chemia produces very similar electrophysiologic effects to b adrenergic receptor gene have been identified and 2 those observed with sodium channel block [48, 49] . Thus, it linked to specific outcomes during drug therapy in asthma is intriguing to think that risk for sudden cardiac death in and to prognosis in patients presenting with congestive general may be related to altered sodium channel function, heart failure [50, 51] . Much less information is available on which could arise through variants not only in the sodium polymorphisms, now increasingly well recognized, in the channel gene itself, but also in any of the multiple genes b receptor. One report did suggest that certain poly-1 that control its normal expression and targeting to the cell morphisms were much more common among patients with surface. Further, this line of reasoning suggests that the dilated cardiomyopathy, but how this would impact drug now well-recognized adverse effects of sodium channel therapy is not yet well-established [52] . block on sudden cardiac death, exemplified in the Cardiac
The ACE gene includes an intronic polymorphism that Arrhythmia Suppression Trial (CAST), arose at least in involves the presence or absence (defining 'insertion' [I] or part through such mechanisms. Testing the concept that 'deletion' [D] alleles respectively) of a 250 base pair some or all of the excess mortality due to sodium channel segment [53] . Subjects with the DD genotype have higher block in CAST has a genetic component would require ACE levels and possibly decreased response to ACE access to DNA of patients in the study, including especialinhibitors, compared to subjects with the II or intermediate ly those who died. Thus, a major implication for a new (ID) genotypes. Whether these associations are sufficiently understanding of the genetic basis of sudden cardiac death robust to predict individual or group responses to ACE and its response to drugs is the imperative that genetic inhibitors with respect to sudden death is not known. material be obtained, where possible, on patient entry into Again, the important implication from CAST as well as the large clinical trials.
large beta blocker and ACE inhibitor trials is that the availability of DNA samples, coupled to well-characterized phenotypic information, will be crucial in future efforts to 8. Pharmacogenetics and the treatment of sudden unravel these questions.
cardiac death
The framework for considering the variability in drug 9. The future action as a cause for adverse drug effects (such as druginduced sudden death) applies equally to prediction of drug One area in which technologies are rapidly evolving is efficacy to prevent sudden death. However, syndromes of that of polymorphism identification. It seems likely that
